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Pre-clinical and clinical studies on dimebon (dimebolin or latrepirdine) have demonstrated its use as a
cognitive enhancer. Here, we show that dimebon administered to 3-month-old C57BL6Nmice 15 min prior to
training in both appetitive and inhibitory learning tasks via repeated (0.1 mg/kg) and acute (0.5 mg/kg) i.p.
injections, respectively, increases memory scores. Acute treatment with dimebon was found to enhance
inhibitory learning, as also shown in the step-down avoidance paradigm in 7-month-old mice. Bolus
administration of dimebon did not affect the animals' locomotion, exploration or anxiety-like behaviour, with
the exception of exploratory behaviour in older mice in the novel cage test. In amodel of appetitive learning, a
spatial version of the Y-maze, dimebon increased the rate of correct choices and decreased the latency of
accessing a water reward after water deprivation, and increased the duration of drinking behaviour during
training/testing procedures. Repeated treatment with dimebon did not alter the behaviours in other tests or
water consumption. Acute treatment of water-deprived and non-water-deprived mice with dimebon also did
not affect their water intake. Our data suggest that dimebon enhances hippocampus-dependent learning in
both appetitive and inhibitory tasks in mice.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Dimebon is a candidate for therapeutics against Alzheimer's
disease, and its clinical activity is currently under investigation. It
was originally developed in 1983 in Russia where it was used as an
antihistamine. Ongoing clinical trials are re-assessing contradictory
results (Miller, 2010) concerning the previously shown efﬁcacy of
dimebon in the improvement of thinking processes and functioning in
patients with mild to moderate Alzheimer's disease (Bachurin et al.,
2001; Doody et al., 2008; O'Brien, 2008; Gura, 2008) and its curative
effects in patients with Huntington's disease (Kieburtz et al., 2010),
also during co-application with other therapeutics. Evaluation of
dimebon against a set of biochemical targets indicated that dimebon
inhibits alpha-adrenergic receptors (alpha1A, alpha1B, and alpha1D,
and alpha2A, alpha 2B, and alpha 2C), histamine H1 and H2 receptors
and serotonin receptors (5-HT-2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6,
and 5-HT7), dopamine receptors (D, D2S, and D3), and imidazoline I2
receptors (Schaffhauser et al., 2009; Giorgetti et al., 2010). At low
concentrations, dimebon potentiates the activity of AMPA-receptors
and blocks NMDA-receptors in neurons (Grigorev et al., 2003).
Pre-clinical studies revealed a number of activities of dimebon in in
vitro and in vivo assays. Dimebon prevents the opening of mitochon-
drial pores induced by neurotoxins, which is regarded as the major
pathogenetic factor of neurodegeneration (Bachurin et al., 2003;
Hung, 2008), elevates extracellular levels of amyloid beta in cell
culture and the hippocampus of freely moving Tg2576 mice (Steele
et al., 2009), promotes neurite outgrowth in cultured hippocampal
and cortical neurons (Protter et al., 2009; Bernales et al., 2009), and
enhances hippocampal neurogenesis (Pieper et al., 2010).
Bolus administration of dimebon in rats resulted in enhancement of
short-term learning in the social recognition paradigm (10 mg/kg, i.p.;
Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 510–522
Abbreviations: H1, H2 receptors, histamine type 1 and 2 receptors; 5-HT-2A, 5-HT2B,
5-HT2C, 5-HT5A, 5-HT6and5-HT7 receptors, 5-hydroxy-tryptamine (serotonin) receptors
types 2A, 2B, 2C, 5A, 6 and 7; D, D2S and D3 receptors, dopamine receptors types 2, 2S
(short form) and 3; I2, imidazoline receptor type 2; AMPA, alfa-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate; NMDA, N-Methyl-D-Aspartate; AF64A, ethylcholine
aziridinium; Tg2576 mice, transgenic mouse with K670N/M671L mutation in APP;
C57BL/6N, inbredmouse inbredmouse strain; ANOVA, analysis of variance; LTP, long-term
potentiation; CA1, CornuAmmonis 1;K1, constant of associationof thedrugwith receptor;
Ach, acetylcholine; AChE, acetylcholinesterase; BrdU, bromodeoxyuridine.
⁎ Corresponding author. School for Mental Health and Neuroscience, Department of
Neuroscience, Maastricht University, Universiteitssingel 50, NL 6229 ER Maastricht,
Netherlands. Tel.: +31 43 38 84 108; fax: +31 43 3671 096.
E-mail address: t.strekalova@maastrichtuniversity.nl (T. Strekalova).
0278-5846/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.pnpbp.2010.12.007
Contents lists available at ScienceDirect
Progress in Neuro-Psychopharmacology & Biological
Psychiatry
j ourna l homepage: www.e lsev ie r.com/ locate /pnp
Schaffhauser et al., 2009) and the novel object recognition task (0.05, 0.5
and 5 mg/kg, p.o.; Giorgetti et al., 2010). In rats treated with the
neurotoxin AF64A, which selectively lesions cholinergic neurons and
impairs active avoidance, 10-day administration of dimebon reversed
these deﬁcits (1 mg/kg/day, i.p.; Lermontova et al., 2000). Similar results
were obtained in the Morris water maze in rats subjected to
intracerebroventricular administration of AF64: chronic administration
of dimebonat thedoseof 0.05 mg/kgrescued spatial learning,whichwas
disrupted by chemical lesion of the dorsal hippocampus (Bachurin et al.,
2006). A single administration of dimebon increased the memory for
newobject localization inyoungC57BL/6Nmice at thedoseof 0.1 mg/kg,
while in a separate experiment, this treatment did not alter the animals'
exploratory activity estimated under the same testing conditions
(Bolkunov et al., in preparation). Performance in a new object
localization model in rodents was shown to be disrupted by selective
lesions of the hippocampus (Galani et al., 1998). Thus, dimebonhasbeen
shown to facilitate learning in various animal models, including para-
digms of hippocampus-dependent learning at a range of concentrations.
Here, we studied whether dimebon applied at the dose that is
efﬁcient in amousemodel of newobject localizationmemory, interferes
with the appetitive learning ofmice in theY-maze. Studies that assessed
dimebon's activity in assays of this type have not been reported to date.
We used a protocol of the Y-maze inmice that was previously validated
as a test for spatial learning (Dolgov et al., 2005; Gorenkova et al., 2005).
In this paradigm, water-deprived C57BL/6N mice were allowed to
orientate themselves by distant visual cues when selecting the arm of
the maze with a ﬁlled bottle. As a model of spatial learning, the Y-maze
paradigm is considered to be a test for hippocampus-dependent
memory (Gerlai, 2001; Liu et al., 2001; Finger et al., 2010; Alhassan
et al., 2009; Tan et al., 2010). We also tested whether dimebon affects
memory in a single trial inhibitory learning paradigm using the step-
down avoidance paradigm, anothermodel for hippocampus-dependent
memory (Lorenzini et al., 1996; Izquierdo andMedina, 1997; Strekalova
et al., 2001, 2001) in young and middle-aged mice. Additionally, we
investigated the potential effects of the drug treatment applied in both
memory tests on parameters of anxiety, exploration and water intake.
The selection of dimebon doses used in this study are based on
previous reports, which demonstrate that a single peripheral admin-
istration of the drug at a dose of 0.05–0.5 mg/kg evokes a memory-
enhancing effect in rats, and results in an effective dimebon brain
concentration of 1.7–14 nM/g, that was suggested to trigger neuro-
chemical processes associatedwith cognitive function (Bachurin et al.,
2006; Giorgetti et al., 2010). Recent studies provide evidence for a
stimulatory effect by dimebon on neurogenesis in the dentate gyrus of
the hippocampus in rats, observed after 1-week of intraperitoneal
injections of the drug applied at the same range of concentrations:
0.1 MKM/kg (0.32 mg/kg; Pieper et al., 2010). Therefore, we antici-
pated that repeated dosing with dimebon at a dose of 0.1 mg/kg, and
single administration of a dose of 0.5 mg/kg, would evoke similar
neurobiological effects as described in the literature.
We demonstrated that administration of dimebon shortly before
training enhances hippocampus-dependent learning in both appeti-
tive and inhibitory learning tasks in C57BL/6N mice. Acute treatment
with dimebon was also shown to enhance inhibitory step-down
avoidance in older animals. In the Y-maze, dimebon increased the
duration of drinking behaviour. Together, our ﬁndings suggest the
memory-enhancing effects of dimebon in two memory paradigms,
which are based on the biologically opposite motivations of positive
reward and aversive stimulation.
2. Methods
2.1. Animals and general conditions of testing
Male C57 BL/6N mice aged 3 and 7 months were used. After
transportation to the experimental facilities, the animals were housed
individually for ten days before the start of experiments under a
reverse 12 h:12 h light–dark cycle (lights on: 22:00 h) in standard
laboratory conditions. Mice were tested during the dark period of the
light cycle in a lab protected from noise. Experimenters were blinded
to the treatment. In order to minimize the possible inﬂuence of the
environment, animals from vehicle- and drug-treated groups were
tested alternately. All experiments were carried out in accordance
with the European Communities Council Directive for the care and use
of laboratory animals following approval by the local governmental
bodies for animal care and welfare.
2.2. Study design
2.2.1. Effects of repeated dimebon administration in the Y-maze
In the ﬁrst study, we investigated the effects of repeated
administration of dimebon on learning to access a bottle with water
after drinking deprivation in a spatial version of the Y-maze. The
dislocation of visual cues impaired the performance of previously
trained mice in the Y-maze protocol, which validated this test as a
model of spatial learning (Gorenkova et al., 2005; Gorenkova and
Strekalova, unpublished results). Naïve 3-month-old male mice were
treated daily either with dimebon (0.1 mg/kg/day) or vehicle (n=8
and n=8, respectively) and 15 min thereafter were trained in two
consequent trials spaced one hour apart; the training lasted 5 days
(Fig. 1A); their latencies for reaching the bottle of water, the
percentage of correct choices and the duration of drinking were
scored (see below). Additionally, the potential effects of acute and 3-
day repeated treatment of dimebon on behaviour in the O-maze and
novel cage were subsequently evaluated 15 min after the injection of
0.1 mg/kg of dimebon (n=8) or vehicle (n=8). On the same day, a
24-h long water consumption test was carried out in repeatedly dosed
animals (Fig. 1C). In a separate experiment, we further addressed the
question of whether dimebon increases thirst in water-deprived
animals (which would elevate their reward during training and
explain the observed accelerated memory acquisition in the Y-maze)
(Fig. 1D). Mice were either not deprived from water or deprived from
drinking for 18 h prior to the test. For each condition, 10 animals were
treated with dimebon at a dose of 0.1 mg/kg 15 min before the onset
of the test and, respectively, 10 and 9 mice were treated by a vehicle.
The amount of consumed water was evaluated 1, 3 and 24 h after the
beginning of the test.
2.2.2. Effects of acute treatment with dimebon in the step-down
avoidance model
As repeated administration of dimebon (0.1 mg/kg) was found to
enhance performance in the Y-maze (see below), we addressed the
question of whether acute treatment with dimebon at this dose affects
hippocampus-dependent learning in a single trial paradigm. Besides,
behavioural changes in dimebon-treated mice were observed in the
Y-maze during the very ﬁrst hours after drug administration.
Therefore, naïve 3-month-old male mice were treated either with
dimebon (dose 0.1 mg/kg) or vehicle and 15 min later were subjected
to a training session in the step-down avoidance model (n=9 and
n=8, respectively); the test for recall was carried out 1 and 24 h later
(Fig. 1B, also see below). Because of the lack of any effects in this
experiment, a higher dose of dimebon (0.5 mg/kg: n=16 and n=17)
was tested in the same study design. Since in this assay, in which
young animals were used, the higher dose of dimebon enhanced
memory, the efﬁcacy of dimebon at a dose of 0.5 mg/kg was further
tested in 7-month-old mice, which received a bolus i.p. injection of
dimebon or vehicle (n=13 in each group) and were tested in the
same protocol of step-down avoidance as used for the younger
animals. In a separate study, 3- and 7-month-old mice were given an i.
p. injection of dimebon at a dose of 0.5 mg/kg (n=8 and n=8 for
each age group, respectively) and 15 min later were tested in the O-
maze and novel cage tests (Fig. 1C; see below) to address the possible
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non-speciﬁc effects of dimebon on parameters of anxiety and
exploration/locomotion.
2.2.3. Apparatus and experimental procedures
2.2.3.1. Y-maze. The apparatus used was a symmetrical Y-shaped
construction made from black Plexiglas, which consisted of three arms
(40×6×10 cm) with an angle of 120° between each arm (Technos-
mart, Rome, Italy). Figures of different shapes (approx. size 20×40
and 20×30 cm) were placed on the walls of the room to allow spatial
orientation. Validation studies showed that the 180°-rotation of cues
around the Y-maze apparatus disrupted the performance of previ-
ously trainedmice (Gorenkova et al., 2005; Gorenkova and Strekalova,
unpublished results). Two bottles, one ﬁlled with water and another
empty, were placed at the ends of the arms in a position adjusted to
allow drinking. The illumination strength was 25 lx.
Before the ﬁrst training session, mice were water-deprived for
18 h. Two 15-min trials per day spaced one hour apart were carried
out for 5 days in a row. The administration of either dimebon or
vehicle was performed 15 min prior to the ﬁrst training session on
each day. During the trial, a mouse was placed at the starting point of
the apparatus (where no bottle was presented) and allowed to access
either arm of the maze containing the bottles, one of which was ﬁlled
with water. Half of each experimental group was trained to receive a
water reward from either the lefthand or righthand bottle. Each
mouse was allowed to drink for up to 15 min in each trial; when no
drinking behaviour was observed by the end of the training day, free
access to water in the home cages was allowed for 30 min one hour
after the termination of behavioural testing. The animals' body weight
was monitored throughout the testing period; previous studies
showed this Y-maze protocol to be optimal for training and
demonstrated a lack of negative effects of the drinking schedule on
body weight (Gorenkova et al., 2005, Gorenkova and Strekalova,
unpublished results). The latency to reach the ﬁlled bottle and the
percentage of correct choices for the arm containing this bottle were
taken as indicators of learning of the task. The total duration of
drinking during each trial was also measured.
2.2.3.2. Step-down avoidance test. Fifteen minutes after the i.p.
administration of drug or vehicle, mice were trained in a step-down
avoidance paradigm. The step-down apparatus (Evolocus LLC Tarry-
town, NY, USA and Technosmart, Rome, Italy) consisted of a
transparent plastic cubicle (25 cm×25 cm×50 cm) with a stainless-
steel grid ﬂoor (33 rods 2 mm in diameter), onto which a square
wooden platform (7 cm×7 cm×1.5 cm) was placed. A shocker was
used to deliver an alternating electric current (AC, 50 Hz). The
illumination strength was 25 lx. In this paradigm, animals will be
trained not to step down from a platform onto a grid ﬂoor to avoid an
electric shock.
During the training session, mice were placed onto the platform
inside a transparent cylinder for 30 s to prevent them from stepping
down immediately. After removal of the cylinder, the time until the
animal left the platform with all four paws was measured as baseline
latency of step down. Immediately after step down, mice received a
single electric foot-shock (0.5 mA, 2 s) and returned to their home
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Fig. 1. Schemes of treatment and behavioural testing. (A) In the Y-Maze paradigm, two-trial training protocol was applied 15 min after an i.p. administration of dimebon or vehicle
during 5 consecutive days. (B) In the step-down avoidance test, single training session was carried out 15 min after an i.p. administration of dimebon or vehicle; mice were tested for
memory recall 1 and 24 h thereafter. (C) Timeline of testing of anxiety-like and exploratory behaviours, and water intake after bolus or repeated administration of dimebon or
vehicle. (D) Timeline of testing the potential effects of bolus dimebon administration on 1-, 3- and 24-h water intake in water-deprived and non-water-deprived mice.
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session, animals were exposed to the apparatus again by being
handled the same way as in the training session; no foot shock was
delivered. Latency of step down with all four paws was measured until
180 s elapsed. Accordingly to a previously validated criterion of the
acquisition of the step down avoidance task (Strekalova and
Steinbusch, 2009, 2010), animals that showed latencies of more
than 30 s in the recall session were considered as good learners. The
behaviour of individual mice, which showed during a recall session
the escape latency 1 s or lower while baseline latency exceeded 5 s,
was regarded as panic response to aversive context, these animals
were discarded from the experiment.
2.2.3.3. O-maze. The apparatus, which consisted of a circular path
(runway width 5.5 cm, diameter 46 cm) was placed 50 cm above the
ﬂoor. Two opposing arms were protected by walls (height 10 cm), and
the illumination strength was 25 lx. The apparatus was placed on the
dark surface in order to reduce a reﬂection and keep a control over
lighting conditions during testing. The anxiety-like behaviour was
assessed in applied protocol of the O-maze test using parameters,
which were validated earlier (Strekalova et al., 2004, 2005). Mice
were placed in one of the close arms compartments of the apparatus.
The latency of the ﬁrst exit to the anxiety-related open compartments
of the maze and total duration of time spent therein were scored
during a 5 min observation period.
2.2.3.4. Novel cage test. The novel cage test was performed to assess
exploration of a new environment (Strekalova et al., 2001, 2004).
Mice were introduced into a standard plastic cage ﬁlled with fresh
sawdust. The number of exploratory rearings was counted under red
light during a 5 min period.
2.2.3.5. Water consumption test in repeatedly treated mice. A 24-
h drinking test was carried out to assess potential effects of repeated
administration of dimebon on water intake (17.00–17.00). Consump-
tion of regular drinking water was evaluated by weighing bottles
before and after the test.
2.2.3.6. Water consumption test in acutely treated mice. To further
evaluate the possible effects of acute dimebon administration on
water intake in water-deprived animals, mice were either not
deprived of water or were deprived from drinking for 18 h. Dimebon
or vehicle was administrated 15 min prior to the test, which was
started at the onset of the dark phase of the light cycle (10.00). Intake
of regular drinking water was measured by weighing bottles 1, 3 and
24 h after the beginning of the test.
2.2.4. Drugs and drug administration
Dimebon (obtained from the Institute of Physiologically Active
Compounds, Chernogolovka, Russia) was dissolved in isotonic NaCl
solution for delivery in a volume of 0.01 ml/g of body weight by
intraperitoneal injection at doses of 0.1 mg/kg and 0.5 mg/kg; vehicle
was administered in the same volume.
2.2.5. Statistical analysis
Data were analyzed with a statistical software package (Prizm 3,
Chicago, IL). Values of latencies to reach water reward in the Y-maze
had normal distribution, therefore, repeated measurements data were
compared by repeated measures ANOVA test followed by the Tukey'
post-hoc test, independent measurements were treated by one way
ANOVA analysis followed by unpaired t-test; differences of variances
were assessed by the F test. Since values of the duration of drinking
behaviour in the Y-maze model in many cases were assigned to a
period of observation, these data were considered as arbitrarily
measured and, therefore, treated by the non-parametric analysis:
Friedman test followed by the Dunn's multiple comparison test was
applied for repeated measurements; Kruskal–Wallis test followed by
Mann–Whitney U-test was used for a group comparison. Percentage
of correct choices was analyzed by a Fischer's exact test. Independent
data sets obtained in the step-down avoidance and O-maze test were
treated with non-parametric analysis, even though the populations
were Gaussian, since in essential percentage of animals behavioural
parameters were measured arbitrary. This was due to the cut off in the
behavioural scoring: several values were assigned to the observation
periods elapsed. Mann–Whitney test was used for the analysis of
independent data sets. Data obtained in the novel cage and water
intake tests had normal distribution and were analyzed by the t-test.
The level of conﬁdence was set at 95% (pb0.05).
3. Results
3.1. Repeated dimebon administration enhances learning in the Y-maze
The effects of daily administration of dimebon on the selection of
the correct arm of the Y-maze baited with a ﬁlled bottle and the
latency to reach the water reward were measured to assess spatial
learning. A repeated ANOVA revealed signiﬁcant changes in the latter
parameter in the course of the 5-day training period both in the
control (p=0.006, F=2.92, R2=0.29) and dimebon-treated groups
(pb0.0001, 10.64, R2=0.60); a decrease in the latency to reach the
water reward (Fig. 2A,B) suggested that mice from both groups
acquired the task. Compared to the mean latency to reach the water
reward measured on day 1 (trial 1), the dimebon-treated group had a
signiﬁcant reduction in this parameter on day 2, while vehicle-treated
mice showed this effect of training only on day 5 (pb0.05; Fig. 2A,B).
ANOVA revealed signiﬁcant differences between dimebon- and
vehicle-treated groups in the overall comparison of latencies to
reach the reward (pb0.0001, F=3.77, R2=0.34). The percentage of
correct choices in the course of nine testing trials (the training trial 1
on day 1 was excluded from the analysis), was signiﬁcantly higher in
the dimebon-treated group (77.8%) than in vehicle-treated mice
(52.78%, p=0.001, Fisher's exact test, Fig. 2C) and chance values
(p=0.0004); the vehicle-treated group showed no signiﬁcant
difference from the chance values for correct choices (p=0.43).
Together, repeated treatment with dimebon accelerated the acquisi-
tion of the Y-maze memory task.
The Friedman test revealed signiﬁcant differences in the duration
of drinking between the trials both in dimebon- and vehicle-treated
mice which spent more time drinking as the experiment progressed
from day 1 to day 5 (pb0.0001 for each group; Fig. 3A,B). This suggests
that animals gradually learnt the location of the water source and
became less anxious in the course of training. The duration of drinking
was signiﬁcantly higher in the dimebon-treated group than in the
vehicle-treated group (on day 1, trial 1: p=0.01, U=11.0; day 2,
trials 1 and 2: p=0.003, U=7.5 and p=0.0005, U=3.0, respectively;
on day 3, trial 2: p=0.01, U=10.5; Mann–Whitney U test; Fig. 3B). A
tendency to increased time spent drinking in the dimebon-treated
mice compared to control animals was revealed in trial 1, day 3
(p=0.06, U=17.0) and in trial 1, day 4 (p=0.06, U=17.5). Starting
from day 4, trial 2 and until the end of the training period, the duration
of drinking did not differ between groups (pN0.05, Mann–Whitney U
test). Thus, in a novel environment, which is well documented to
induce anxiety and suppress consummatory behaviour (Loiseau et al.,
2003; Dulawa and Hen, 2005), mice repeatedly treated with dimebon
showed elevated water intake. The latter ﬁnding suggested that drug
administration might induce an anxiolytic-like effect and/or change
the physiological need for water. To rule out these factors, additional
experiments were carried out.
Since signiﬁcant effects of dimebon on the latency to reach a
reward and the duration of drinking behaviour were revealed both
after repeated treatments, the potential effects of repeated dimebon
administration was assessed in additional tests. It was found that the
3-day treatment with dimebon at a dose of 0.1 mg/kg, compared to a
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vehicle-treated group, did not change the latency of exit, the time
spent in the open arms or the number of exits in the O-maze (pN0.05
and pN0.05 respectively, Mann–Whitney U test; Fig. 3C). In particular,
the difference in time spent in the open arms of the O-maze between
the dimebon- and vehicle-treated group was far from statistically
signiﬁcant (p=0.79, U=29). No difference was found between
vehicle- and dimebon-treated groups in the number of exploratory
rearings in the novel cage either (pN0.05 and pN0.05 respectively,
unpaired t-test; Fig. 3D).
Repeated dosing with dimebon did not alter the 24-h water intake
(pN0.05, unpaired t-test; Fig. 3E). In addition, in order to determine
whether acute administration of dimebon can increase thirst in
water-deprived animals, we studied the effects of dimebon on mice
under normal and water-deprivation conditions. Bolus injection of
dimebon did not affect 1-h, 3-h or 24-h water consumption regardless
of previous water deprivation (pN0.05, two-way ANOVA; Fig. 3F). The
amount of water consumed did not differ between vehicle-treated
and dimebon-treated mice not deprived of water, or between animals
previously deprived of water (pN0.05 and pN0.05 respectively,
Mann–Whitney U test; Fig. 3F). A two-way ANOVA showed that
water-deprivation increased water intake at three time points
(pb0.05, two-way ANOVA). Together, our results suggest that
treatment with dimebon at a dose of 0.1 mg/kg accelerates spatial
learning of the task based on water reward without affecting the
metabolic requirement for water, locomotion or exploration in mice.
However, dimebon seemed to have an anxiolytic-like effect in the
model of spatial learning, which may have contributed to the
improvement of performance under the testing conditions employed.
Fig. 2. Repeated dimebon administration accelerates learning in the Y-Maze. (A) Individual and (B) group data demonstrate a signiﬁcant reduction of the latency to reach the water
reward in dimebon-treated group on days 2–5 of training, while vehicle-treated group showed such difference on day 5 (#pb0.05 vs. training values on Day 1 Trial 1, Tukey's posthoc
test). On days 3 and 5, this parameter was signiﬁcantly lower in dimebon-treated animals than in vehicle-treated mice (⁎pb0.05, unpaired t-test). Bars represent the means; each
column represents the mean±SEM. (C) Percentage of correct choices for the armwith a ﬁlled bottle from nine testing trials overall carried out for 8 animals was signiﬁcantly higher
in dimebon-treated group than in control group (⁎pb0.05, Fischer's exact test). Absolute numbers of correct choices are indicated above the bars. NaCl: vehicle-treated group; and
Dim: dimebon-treated group.
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Fig. 3. Effects of repeated administration of dimebon on parameters of anxiety, locomotion, exploration and drinking. (A) Individual and (B) group data evidence signiﬁcant increase
of drinking behaviour in a course of training experiment in the Y-Maze (#pb0.05 vs. training values on Day 1 Trial 1, Dunn's multiple comparison test). Duration of drinking was
signiﬁcantly higher in dimebon-treated mice than in control group on days 1–3 (⁎pb0.05, Kruskal–Wallis test). Bars represent the medians. Each column represents the mean±SEM.
Mice, repeatedly treated with dimebon did not differ from vehicle-treated animals in (C) latency of exit to open arms and time spent therein, as well as number of exits in the O-
maze, (D) number of exploratory rearings in the novel cage test, (E) 24-h water intake; pN0.05, Mann–Whitney U-test. (F) Bolus treatment with dimebon does not affect 1-, 3- and
24-h water intake, regardless of preceding water deprivation (pN0.05, two-way ANOVA), which increased 24-h water consumption both in vehicle- and dimebon-treated groups
(see text). Each column represents the mean±SEM. NaCl: vehicle-treated group; Dim: dimebon-treated group; WD: water-deprived; and nWD: non-water-deprived.
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3.2. Acute treatment with dimebon increases performance in the step-
down avoidance model
In the above-described experiment, dimebon-treated mice
showed behavioural changes during the course of a repeated
training/dosing protocol and also immediately after the very ﬁrst
drug administration (within a 2-h period), comprising a signiﬁcant
increase in the duration of drinking behaviour (Figs. 2,3). Therefore,
we addressed the question of whether a bolus injection of dimebon at
the dose of 0.1 mg/kg can affect learning in a single trial memory
model in 3-month-old mice using the step-down avoidance paradigm.
The vehicle- and dimebon-treated groups showed similar baseline
latencies (p=0.35, U=21.00, Mann–Whitney U test) suggesting that
dimebon injection is unlikely to affect locomotion, exploration or
anxiety-like behaviours in the step-down avoidance test. In compar-
ison to the baseline values, the latencies of step down were similarly
increased in vehicle- and dimebon-treated groups during the ﬁrst
recall session (p=0.02 and p=0.04, respectively, Wilcoxon test;
Fig. 4A,B) and the second recall session (p=0.01 and p=0.01
respectively), indicating that both experimental groups acquired the
task.
We found no differences between the groups in the latency of step
down in either of the two recall sessions, carried out 1 or 24 h after
training (p=0.28, U=19.0 and P=0.45, U=23.5 respectively,
Mann–Whitney U test; Fig. 4B). According to our exclusion criteria
(see Methods section) three mice were discarded from the experiment
(one from the control group and two from the dimebon-treated
group). The number of animals that were classiﬁed as good learners
according to the 30-sec criterion of the task acquisition (see Methods
section) among vehicle- and dimebon-treated mice was similar during
Fig. 4. Acute treatment with dimebon enhances performance in the step-down avoidance paradigm: effects in 3- and 7-month old mice. (A, D, G) Individual and (B, E, H) group data
show an increase of the latencies of step down measured during two recall sessions(+1 h and +24 h) in comparison to the training session (baseline) in vehicle and dimebon-
treated group suggesting that mice acquired the task (#pb0.05 vs. training values, Wilcoxon test). Three- and seven-month old mice treated with dimebon at the dose of 0.5 mg/kg
revealed signiﬁcant increase in the latency of step down evaluated 24 h after training as compared to vehicle-treated group (⁎pb0.05, Mann–Whitney U-test); no such difference
was observed in 3-month old mice treated by 0.1 mg/kg of dimebon (pN0.05, Mann–Whitney U-test). Seven-month old mice treated with dimebon showed also a signiﬁcant
increase of this parameter 1 h after training, as compared to vehicle-treated animals (⁎⁎pb0.05, Mann–Whitney U-test). (C, F, I) Three- and seven-month old mice treated with
dimebon at the dose of 0.5 mg/kg had signiﬁcantly higher percentage of good learners estimated 24 h after training as compared to vehicle-treated group (⁎pb0.05, Fischer's exact
test); no such difference was observed in 3-month old mice treated by 0.1 mg/kg of dimebon (pN0.05, Fischer's exact test). Seven-month old mice treated with dimebon showed also
a signiﬁcant increase of this parameter 1 h after training, as compared to vehicle-treated animals (⁎⁎pb0.05, Fischer's exact test). Each column represents the mean±SEM. NaCl:
vehicle-treated group; and Dim: dimebon-treated group.
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the ﬁrst and second recall sessions (p=0.50 and p=0.77 respective-
ly, Fischer's exact test; Fig. 4C). Thus, acute injection of dimebon at the
dose of 0.1 mg/kg does not alter short-term and contextual learning in
mice trained in the step-down avoidance task.
In the next experiment, we studied whether a higher dose of
dimebon (0.5 mg/kg) would change the performance in the step-
down avoidance model assessed in the same experimental design. As
in a previous study, drug administration did not affect the baseline
latencies of step down, which were similar in vehicle-treated and
dimebon-treated mice (pN0.05, Mann–Whitney U test; Fig. 4D,E). The
latencies of step down were increased during recall sessions in both
groups in comparison to baseline values, both during the ﬁrst recall
trial (p=0.05 and p=0.001 for vehicle- and dimebon-treated groups,
respectively, Wilcoxon; Fig. 4D,E) and during the second recall session
(p=0.06 and p=0.01, respectively). Whereas no difference in the
latency of step down between the groups was observed during the
ﬁrst recall session (p=0.18, U=90.0, Mann–Whitney U test; Fig. 4D,
E), the dimebon-treated group showed a signiﬁcantly longer latency
of step down during the second recall session compared to vehicle-
treated mice (p=0.03, U=67.5, Mann–Whitney U test). In addition,
the percentage of good learners was signiﬁcantly higher among
dimebon-treated animals than in vehicle-treated mice during the
second recall session (p=0.03, Fischer's exact test, Fig. 4F). Three
mice were discarded from the experiment (one from the control
group and two from the dimebon-treated group), according to the
exclusion criteria (see Methods section). The results of this experiment
demonstrate improved scores of long-term memory of mice treated
with a bolus i.p. injection of dimebon at a dose of 0.5 mg/kg in a step-
down avoidance paradigm.
To verify these effects of dimebon in slightly different conditions,
we used 7-month-old mice in the same study design. The adminis-
tration of dimebon did not alter the baseline latencies of step down,
which did not differ signiﬁcantly between the vehicle and dimebon-
treated mice (pN0.05, Mann–Whitney U test; Fig. 4G,H). In vehicle-
and dimebon-treated groups, the latencies of step down were
elevated during recall sessions in comparison to baseline values,
both during the ﬁrst recall trial (p=0.0008 and pb0.0001 for
respectively, Wilcoxon; Fig. 4D,E) and during the second recall
session (pb0.0001 and p=0.0004, respectively; Fig. 4G,H). The
dimebon-treated group showed a signiﬁcantly higher latency of step
down during the second recall session than vehicle-treated mice
(p=0.03, U=63.0; Mann–Whitney U test; Fig. 4G,H) and during the
ﬁrst recall session (p=0.03, U=67.0). The percentage of good
learners was signiﬁcantly higher in the dimebon-treated than control
mice during the ﬁrst and second recall sessions (p=0.04 and p=0.01,
respectively; Fisher's exact test, Fig. I). According to the exclusion
criteria (see Methods section) ﬁve mice were excluded from the
experiment (one from the control group and four from the dimebon-
treated group). Thus, bolus i.p. injection of dimebon at a dose of
0.5 mg/kg also elevates memory scores in a step-down avoidance
paradigm in 7-month-old mice. These results further demonstrate the
memory-enhancing effects of a single administration of dimebon at a
dose of 0.5 mg/kg in a step-down avoidance model.
To rule out the possibility that dimebon, at a dose that affects
performance in the step-down avoidance model, interferes with
anxiety-like behaviour and exploration, supplementary tests were
carried out in young and middle-aged mice. Application of a battery of
tests 15 min after intraperitoneal administration of dimebon and
vehicle in 3-month-old and 7-month-old mice at a dose of 0.5 mg/kg
revealed a lack of differences between the groups in the latency of exit,
time spent in the open arms and the number of exits in the O-maze
(pN0.05, Mann–Whitney U test, Fig. 5A,D). Of note, while 3- and 7-
month-old dimebon-treated mice show a graphical trend towards
decreased time spent in the open arms of the O-maze, the difference in
this parameter from the vehicle-treated group is far from statistically
signiﬁcant (p=0.88, U=30 and p=0.28, U=21.5, respectively).
The number of exploratory rearings in the novel cage was
unchanged in young mice treated with dimebon (pN0.05, unpaired
t-test; Fig. 5B) and was signiﬁcantly lower in older mice after dimebon
administration (p=0.04, unpaired t-test; Fig. 5E). Thus, the statisti-
cally signiﬁcant increase in the latency of step down in 7-month-old
mice treated with dimebon during the ﬁrst recall session can be
accounted for by the general suppressive effect of the treatment on
exploration/locomotion; these effects were observed in 3-month-old
animals. Together, our results suggest that similar to the experiment
on young animals, bolus treatment with dimebon at a dose of 0.5 mg/
kg enhances long-term contextual learning in the step-down model in
middle-aged mice.
4. Discussion
The present data suggest that the administration of dimebon
15 min prior to training in the Y-maze and step-down avoidance via
repeated (0.1 mg/kg) and acute (0.5 mg/kg) i.p. injections, respec-
tively, increases learning scores in C57BL/6N mice while affecting
other behaviours in some test situations, as well (Table 1). Bolus
administration of dimebon at the dose of 0.1 mg/kg did not alter the
learning of the step-down avoidance task in 3-month-old mice. Acute
treatment with dimebon was also shown to enhance inhibitory
learning in the 7-month-old mice. Bolus administration of dimebon
did not affect locomotion, exploration or anxiety-like behaviour in
additional experiments in young and old mice, except rearing activity
in 7-month-old mice in a novel cage test, which was decreased by the
treatment. No effects of 3-day treatment with dimebon on locomo-
tion, exploration, O-maze behaviour or water consumption were
found either. Repeated administration of dimebon increased the
duration of drinking behaviour in the Y-maze. Together, our data
suggest that in mice, dimebon increases hippocampus-dependent
learning in both appetitive and inhibitory tasks. Thus, dimebon
enhances memory based on the biologically opposite situations of
positive reward and aversive stimulation.
In the course of training in the Y-maze, dimebon-treated mice
showed overall shorter latencies of reaching the water reward than
control mice (Fig. 2A,B). Dimebon-treated mice revealed a signiﬁcant
reduction in this parameter compared to the values measured on day
1, trial 1, starting from day 2, trial 2 of the training procedure, while
control animals demonstrated such an effect of training only on day 5.
On days 3 and 5, the dimebon-treated group had signiﬁcantly shorter
latencies to reach the water reward than the vehicle-treated group.
The percentage of correct choices was signiﬁcantly higher in the
dimebon-treated group than in control mice (Fig. 2D). Together, our
data suggest that repeated treatment with dimebon accelerated the
acquisition of the spatial task in the Y-maze test.
Importantly, acute and chronic administrations of dimebon
signiﬁcantly increased the duration of drinking during the ﬁrst
experimental session and in the course of daily training (Fig. 3A,B).
As anxiolytic drugs are well-documented to increase novelty-
suppressed consummatory behaviour (Loiseau et al., 2003; Dulawa
and Hen, 2005) and the anxiolytic effects of dimebon were observed
in two classical tests for anxiety-like behaviour and open ﬁeld tests
(Bachurin and Grigoriev, 2009), our ﬁndings might be considered to
be an indication of the anti-anxiety properties of dimebon. In the
latter study, bolus intraperitoneal administration of dimebon at a dose
of 2 mg/kg, 40 min prior to testing was found to induce an anxiolytic
effect in a rat Vogel conﬂict model, dark/light box paradigm, and an
open ﬁeld test, that was similar to the effects of diazepam applied at
the same dose. Lower doses of dimebon (0.05–0.1 mg/kg) evoked
anxiolytic-like changes in some, but not all behavioural measures in
this study. In our experiments, repeated 3-day treatments with
dimebon did not alter anxiety-like behaviour in the O-maze (Fig. 3C),
and similar results were found after bolus treatment with dimebon at
a dose of 0.5 mg/kg in 3-month-old and 7-month-old mice (Fig. 5A,C,
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Fig. 5. Bolus injection of dimebon and parameters of anxiety, locomotion and exploration. Three-month old mice, treated with dimebon did not differ from vehicle-treated animals in
(A) latency of exit to open arms and time spent therein, as well as number of exits in the O-maze (pN0.05, Mann–Whitney U-test) and (B) number of exploratory rearings in the
novel cage test (pN0.05, unpaired t-test). (C) Seven-month old mice, treated with dimebon did not differ from vehicle-treated animals in the latency of exit to open arms and time
spent in the open arms, as well as in the number of exits in the O-maze (pN0.05, Mann–Whitney U-test), but (B) showed reduced number of exploratory rearings in the novel cage
test (⁎pb0.05, unpaired t-test). Each column represents the mean±SEM. NaCl: vehicle-treated group; and Dim: dimebon-treated group.
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see also below). Mice treated with dimebon demonstrated an
insigniﬁcant decrease in the duration of time spent in the O-maze;
statistically, this difference was far from signiﬁcant, and is due to the
presence of a few outliers. The latency of exit to open arms, and the
number of exits had similar values in vehicle- and dimebon-treated
groups, thus additionally suggesting a lack of effect by dimebon on
anxiety-related behaviour under these testing conditions.
The differences between our experimental results and the above
described study might be due to differences in dimebon doses, species
and anxiety paradigms employed, as well as distinct animal testing
times with respect to dosing. In order to rule out potential confounds
in the evaluation of the cognitive effects of dimebon, mice were tested
in O- and Y-mazes using consistent time schedules, 15 min after drug
administration in both tests. In contrast to this testing protocol,
changes in the anxiety-like behaviour of dimebon-treated rats were
investigated at a time point which is believed to be closer to the peak
of dimebon concentration in the brain, as other studies have revealed
maximal levels of the drug in the rat brain 50–60 min after its
intragastrical administration at doses of 0.05–1 mg/kg (Giorgetti et al.,
2010). As these doses of dimebon were similar to those used in the
present study, we assume that the concentration of dimebon in the
brain peaks during a comparable time period, i.e. 30 min–1 h 30 min
after dosing. Thus, it can be speculated that among other possible
reasons, the anti-anxiety effects of dimebon in the O-maze experi-
ment were not observed because of lower concentrations of the drug
in the mouse brain at the moment of testing in this paradigm. In
support of this explanation, we found that in the Y-maze, a signiﬁcant
prolongation of drinking behaviour in dimebon-treated mice was
detected on Day 1, Trial 2, i.e. approximately 1 h after the ﬁrst drug
administration, but not during testing in Trial 1, which was carried out
only 15 min after treatment (Fig. 3A,B). Together, our results in the Y-
and O-maze paradigms, and previously obtained data on the
inconsistent appearance of the anti-anxiety effects of dimebon in
rats treated with low drug doses, led us to suggest that the proposed
anxiolytic-like action of this compound does not occur in all test
situations. Similar results were found for other drugs as well (Haller
et al., 2000; Merali et al., 2003; Reddy and Devi, 2006).
Suggested anxiolytic-like effect of dimebon in the Y-maze might
contribute to the animals' performance by the facilitation of mouse
exploration in the anxiogenic situation of novelty, which generally
increases the chances of ﬁnding a bottle with water and receiving a
reward. In addition, the enhanced rewarding impact of the training
procedure may be due to the prolongation of water intake in water-
deprived mice; increased reward during training may accelerate the
acquisition of the Y-maze appetitive task above and beyond the
immediate effects of dimebon as a cognitive enhancer.
Supplementary tests rule out the possibility that dimebon merely
increases exploratory behaviour (Fig. 3D) and elevates the metabolic
need for water; the latter factor was assessed for repeated bolus
administration of dimebon in both water-deprived mice and under
normal drinking conditions (Fig. 3E,F). Bolus injection of dimebon did
not increase 1-, 3- or 24-h water intake, regardless of previous water
deprivation. Moreover, after acute treatment with dimebon, 24-
h water intake was insigniﬁcantly decreased in non-water deprived
animals in this study (Fig. 3F), in line with earlier reported
suppressive effects of other drugs with inhibitory action on various
behaviours in rodents, e.g., citalopram, on water consumption
(Strekalova et al., 2006). Hence, possible changes in exploration and
thirst did not seem to interfere with enhanced performance in the Y-
maze and increased duration of drinking behaviour of animals treated
with dimebon.
Thus, dimebon enhances spatial learning in the memory model
based on positive reward. Because novelty exploration is also
considered to be a rewarding stimulus, the memory enhancing effects
of dimebon in the new object exploration/localization paradigms
mentioned above and described by other groups (Chuhan and
Taukulis, 2006; Giorgetti et al., 2010) indirectly support our ﬁndings.
Since in the Y-maze, the very ﬁrst administration of dimebon
induced behavioural changes (increasing the duration of drinking
behaviour; Fig. 3A,B), we tested whether dimebon affected learning
after a bolus injection. To achieve consistency with the Y-maze study,
we selected the step-down avoidance paradigm, since this is a single
trial memory test in which the animals' performance is well known to
depend on intact hippocampal function (Lorenzini et al., 1996;
Izquierdo et al., 2006). The object recognition test was not selected,
since there are discrepancies concerning the role of the hippocampus
in this task (Albasser et al., 2010).
We found that dimebon delivered at the dose of 0.5, but not
0.1 mg/kg signiﬁcantly increased the latency of step down in a recall
session carried out 24 h after the training session (Fig. 4A,B,D,E), as
well as the number of animals classiﬁed as good learners (Fig. 4C,F) in
3-month-old mice, i.e., it evoked memory-enhancing effects, accord-
ing to previously validated criteria of memory acquisition in this task
(Strekalova and Steinbusch, 2009, 2010). Changes in the latency to
step down under conditions of intrahippocampal administration of
various active compounds and the induction of stress-induced
anhedonia have been shown to correlate with other parameters of
hippocampal plasticity, such as induction of the LTP in the CA1 area of
the hippocampal formation (Strekalova et al., 2001, 2002; Strekalova
and Steinbusch, 2010; Tokarski et al., under revision). The effective
dose of dimebon also increased learning scores in the step-down
avoidance test in 7-month-old mice (Fig. 4G–I). No changes in the
latency to step down were found in dimebon-treated mice tested 1 h
after the training session in young mice, while in 7-month-old
animals it was signiﬁcantly increased in the dimebon-treated group
(Fig. 4E,H).
However, dimebon at the dose of 0.5 mg/kg inhibited exploration/
locomotion in the novel cage test in the older, but not younger
animals (Fig. 5A,D). Given the lack of memory-enhancing effects on
short-term memory in young mice, these data suggest that a
signiﬁcant increase in the latency to step down revealed in 7-
month-old mice treated with dimebon during the ﬁrst recall session
was due to its non-speciﬁc inhibitory effects on locomotion. Data on
the suppressive effects of dimebon on exploratory vertical activity in
the novel cage are in line with the well-documented sedative effects
of histamine receptor blockers (Passani et al., 2007; Van Ruitenbeek et
Table 1
Memory enhancing action and other behavioural effects of acute and repeated treatment with dimebon. Dimebon induced memory enhancing effect at the dose of 0.1 when injected
repeatedly and at the dose of 0.5 when applied acutely. Both types of treatment induced also other behavioural effects (see text; n.a.: non-applicable).
Acute treatment Repeated treatment
Memory enhancing Other effects Memory enhancing Other effects
Y-maze 3-m-o
0.1 mg/kg
– + + +
Step down avoidance 3-m-o 0.1 mg/kg – –
0.5 mg/kg + –
7-m-o 0.5 mg/kg + + n.a. n.a.
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al., 2010), which are more subtle with dimebon treatment than with
other antihistamines (Iliyuchenok and Matveeva, 1989). Similarly to
our study, dimebon was found to decrease exploratory behaviour in
rats at a dose of 30 mg/kg (Schaffhauser et al., 2009). Interestingly, the
inhibitory action of dimebon on exploratory rearing activity in the
novel cage was age-dependent. Other studies have revealed differen-
tial effects of psychotropic drugs, including compounds with sedative
activity, on younger vs. older rodents (Smith et al., 2002; Takase et al.,
2009). The distinct locomotory effects of dimebon on 3- and 7-month-
old mice in the present work might be accounted for by altered
receptor sensitivity and slower drug metabolism, resulting in elevated
dimebon concentrations in the brains of older animals.
Inhibitory behavioural effects of dimebon in 7 month-old-mice on
exploratory rearing activity and step down avoidance behaviour
measured shortly after training were detected 0.5 h and 1 h 15 min
after the treatment, respectively, thus, the occurrence of these effects
of dimebon corresponded a proposed time window of maximal brain
concentrations of the drug in the mouse brain. No such effects of the
treatment were revealed at earlier time points relative to the
treatment, as no changes were observed in the latency of baseline
step down behaviour and parameters reﬂecting animals' locomotion
in the O-maze, which were assessed 15 min after injection of a dose
dimebon.
The fact that the dimebon- and vehicle-treated groups in both age
groups showed no difference in their baseline latencies of step down
which demonstrates the absence of its effects on anxiety and
locomotion under conditions of testing in the step-down avoidance
apparatus. In line with these data, most of the supplementary tests in
mice of both age groups revealed no effects of dimebon on the
parameters of anxiety-like behaviour in the O-maze test (Fig. 5A,C) or
exploratory behaviour in the novel cage test (Fig. 5B) with the above-
mentioned exception of the behavioural inhibition of 7-month-old
mice in the latter paradigm (Fig. 5D). Similarly to the study results on
the effect of repeated dimebon administration, both 3- and 7-month-
old animals acutely treated with dimebon demonstrated an insignif-
icant decrease in the duration of time spent in the O-maze; these
differences were far from the level of statistical signiﬁcance. Single
outliers, which might represent individual mice with increased
sensitivity to the drug or/and testing procedures, could contribute
to these insigniﬁcant changes. Of note, the latency of exit to open arms
and the number of exits were virtually the same between the groups,
again suggesting a lack of effect by dimebon on anxiety-related
behaviour in the O-maze in our study. Thus, these data rule out the
possibility of non-speciﬁc effects of dimebon on mouse performance
in the step-down avoidance model for young animals.
All together, presented data suggest that dimebon enhances
learning in both appetitive and inhibitory tasks of the hippocampus-
dependent memory in mice. As it was mentioned above, dimebon
administrated to a rat at the dose of 0.05–1 mg/kg was found to have a
half-life in the plasma over 2 h (Giorgetti et al., 2010); similar doses
used in the present work led to expect comparable pharmacokinetics
of dimebon in employed here battery of memory tests. Together with
the fact that dimebon was delivered 15 min prior to training, this let
to propose that dimebon was present at an effective concentration in
the mouse brain during phases of early and intermediate memory
consolidation in both the Y-maze and step-down avoidance models
(Gerlai, 2001; Cammarota et al., 2005; Da Silva Costa et al., 2009;
Benchenane et al., 2010). The relatively short half-life of dimebon in
rodents suggests that the non-speciﬁc effects of dimebon observed
within 30 min after drug administration in the novel cage test are
unlikely to underlie an increase in the latency of step down
documented 24 h after training in the step-down avoidance para-
digm. These changes are very likely to reﬂect the memory-enhancing
effects of dimebon administration.
The mechanism underlying the memory enhancing effects of
dimebon remains elusive. During the last few decades, the concept of
multi-target drug activity has been proposed (Wong et al., 2008;
Cavalli et al., 2008; Combarros et al., 2009). According to this concept,
the mechanisms responsible for the beneﬁcial actions of drugs can be
realised via multiple actions of the compound on a number of
receptors; in this case, effective changes in the concentrations of
neurotransmitters may be much lower than if only one receptor
signaling system underlies the drug's activity. On one hand, dimebon
was shown to interact with a broad spectrum of neuronal receptors,
which are involved in synaptic plasticity and cognitive functions
(Lermontova et al., 2001; Schaffhauser et al., 2009; Grigoriev, 2009;
Giorgetti et al., 2010; Okun et al., 2010). At the same time, effects from
dimebon on pre-clinical and clinical measures of cognition were
found at doses corresponding to brain concentrations much lower
than the K1 values for many receptors which were found to be
effective in models of learning and memory (Gold, 2006). Thus, it can
be speculated that, in the mouse test battery employed in this study,
dimebon affects a number of receptors and may act as a multi-target
drug, i.e. the concentrations used in this study, which correspond to
sub-threshold levels for receptor activation via a mono-target
mechanism, are only able to evoke physiological effects by synergistic
activation of several neurotransmitter systems (Youdim and Bucca-
fusco, 2005; Cavalli et al., 2008). The memory-enhancing effects of
dimebon may indicate simultaneous activity toward AMPA, NMDA,
dopamine and serotonin receptors, all of which have been involved in
inhibitory and appetitive hippocampus-dependent learning (Ungerer
et al., 1998; Orsetti et al., 2001; Rogawski and Wenk, 2003; LaLumiere
et al., 2003; Lynch and Gall, 2006; Balschun et al., 2006; Da Silva Costa
et al., 2009; Benchenane et al., 2010). In particular, it has been
hypothesised that dimebon's activity as a positive modulator of AMPA
receptors and low afﬁnity non-competitive blocker of NMDA
receptors via a multi-drug mechanism, can explain the pro-cognitive
action of this compound (Grigorev et al., 2003; Grigoriev 2009).
The last data suggest that it is unlikely that the effects of dimebon
on memory presented here and in other reports occur via its action on
neurotransmitter systems via a “one drug–one molecule” mechanism.
For instance, a recent study showed that intragastrically delivered
dimebon at a dose of 0.05–5.0 mg/kg is inefﬁcient at the inhibition of
AChE or blockade of the NMDA receptor; these doses, however,
evoked pronounced improvement of new object recognition memory
in rats. This dose range of dimebon did not affect the turnover of ACh
in the hippocampus and prefrontal cortex, and is ineffective at
blocking the NMDA-induced calcium inﬂux; both effects observed at
higher dimebon concentrations (Giorgetti et al., 2010; Wu et al.,
2008). In another study, dimebon was found to bind to 5-HT6
receptor, where it enhanced social recognition memory; however, the
weak binding afﬁnity and the relatively low drug concentrations
employed in the study cannot link the observed behavioural effects to
changes in serotonin transmission (Schaffhauser et al., 2009). In
addition, dimebon was shown to bind to a number of receptors, such
as histamine, dopamine, norepinephrine and serotonin receptors, at
concentrations which are not comparable to those used in vivo (Wu
et al., 2008; Schaffhauser et al., 2009; Giorgetti et al., 2010). In sum, at
present, a consistent view on the neurotransmitter mechanism that
underlies the memory-enhancing effects of dimebon is lacking.
Interestingly, a recent study reported that dimebon had remark-
able effects on hippocampal neurogenesis, at doses comparable to
those used in the present study (Pieper et al., 2010). One-week
treatment of rats with dimebon at a dose of 0.1 mkM/kg (0.32 mg/kg)
increased the number of BrdU-positive cells in the dentate gyrus.
Because activation of structural plasticity and neurogenesis in the
hippocampus is well demonstrated to be implicated in the mecha-
nisms of contextual and spatial learning (Epp et al., 2007; Yang et al.,
2008; Li et al., 2010; Pieper et al., 2010), we suggest that this effect
might be one of the potential mechanisms which underlie the
memory enhancing action of dimebon observed in the current
study. Further experiments are required to address the possible link
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between the mnemonic effects of dimebon and its properties as a
proneurogenic compound.
5. Conclusion
Recently, a series of new functional analogues of dimebon with
predominant action on several proposed mechanisms discussed
above was developed (Lermontova et al. 2003; Perlovich et al.,
2009; Bachurin et al., unpublished results). A comparative analysis of
these compounds in the battery of tests employed in the current study
will hopefully help to elucidate its mechanism of memory-enhancing
action in the future. Since the hippocampus was shown to be a
primary brain structure, the function of which is compromised during
early stages of Alzheimer's disease (Foerstl, 2009), this suggests the
usefulness of the battery of mouse models of hippocampus-dependent
memory employed in the present work for such studies as well as, in
general, for fundamental and pre-clinical aspects of testing drug
candidates for the treatment of this pathology.
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